# Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

> **NCT00866476** · PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 20 (actual)

## Conditions studied

- Shigella

## Interventions

- **BIOLOGICAL:** CVD 1208S, a Shigella flexneri 2a live, oral vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00866476
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Reactogenicity met study halting criteria
- **Last updated:** 2021-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866476, "Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00866476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*